Generic placeholder image

Current Radiopharmaceuticals

Author(s): Muhammad Isa Khan, Umme Farwa, Tahir Iqbal, Saadat Ali, Aalia Nazir and Mohsin Ijaz*

DOI: 10.2174/1874471012666190620144803

DownloadDownload PDF Flyer Cite As
Comparison of 99mTc Injected Activity with Prescribed Activity in Four Types of Nuclear Medicine Exams

Page: [80 - 85] Pages: 6

  • * (Excluding Mailing and Handling)

Abstract

Background: 99mTc is a radioactive isotope that is obtained by eluting a 99Mo/99mTc generator. (PINSTECH, Islamabad) and used for radionuclide scanning.

Objectives: The objective of this work is to study the uncertainties in 99mTc activity that exist due to time delay between injection preparation and administration to patients, during the process of gamma camera scanning.

Methods: Lead canisters were used for storing elution vials and dose calibrator for measuring 99mTc activity in mCi. The activity of preparing 99mTc injection and its administration to patients were compared with the prescribed values of activity recommended in the Society of Nuclear Medicine procedure guidelines.

Results: This study showed that uncertainty in the activity existed in one thyroid patient, 38 bone patients, 5 renal patients and 45 cardiac patients.

Conclusion: This uncertainty in activity exists due to time delay between injection preparation and administration to patients, as well as due to residual radionuclide that is not injected into patients and remains in the syringe.

Keywords: 99Mo/99mTcgenerator, radiopharmaceutical, 99mTc, dose calibrator, lead canisters, thyroid patient, cardiac patients, bone scintigraphy, MDP.

Graphical Abstract

[1]
Taylor, A.T.; Brandon, D.C.; de Palma, D.; Blaufox, M.D.; Durand, E.; Erbas, B.; Grant, S.F.; Hilson, A.J.W.; Morsing, A. SNMMI Procedure Standard/EANM Practice Guideline for Diuretic Renal Scintigraphy in Adults With Suspected Upper Urinary Tract Obstruction 1.0. Semin. Nucl. Med., 2018, 48(4), 377-390.
[http://dx.doi.org/10.1053/j.semnuclmed.2018.02.010] [PMID: 29852947]
[2]
Saha, G.B. Fundamentals of Nuclear Pharmacy, 5th ed; Springer: New York, 2010.
[http://dx.doi.org/10.1007/978-1-4419-5860-0_6]
[3]
Pirdamooie, S.; Shanei, A.; Moslehi, M. Comparison of the Absorbed Dose for (99m)Tc-Diethylenetriaminepentaacetic Acid and (99m)Tc-Ethylenedicysteine Radiopharmaceuticals using Medical Internal Radiation Dosimetry. J. Med. Signals Sens., 2015, 5(3), 171-175.
[http://dx.doi.org/10.4103/2228-7477.161489] [PMID: 26284173]
[4]
Prvulovich, E.M.; Bomanji, J.B. The role of nuclear medicine in clinical investigation. BMJ, 1998, 316(7138), 1140-1146.
[http://dx.doi.org/10.1136/bmj.316.7138.1140] [PMID: 9552956]
[5]
Chandra, R. Nuclear Medicine Physics :The Basics. 7th ed. Medical Physics, 2012, 39(10), 6525.
[6]
Deutsch, E.A.; Libson, K.; Jurisson, S. Technetium chemistry and technetium radiopharmaceuticals, Progress in Inorganic Chemistry; Lippard, S.J., Ed.; John Wiley & Sons: New York, 1983, pp. 75-139.
[7]
Gupta, T.K. Radiation, Ionization, and Detection in Nuclear Medicine; Springer, 2013, pp. 451-494.
[http://dx.doi.org/10.1007/978-3-642-34076-5_9]
[8]
Williams, C.C.; Kereiakes, J.G.; Grossman, L.W. The accuracy of 99Molybdenum assays in 99mTechnetium solutions. Radiology, 1981, 138(2), 445-448.
[http://dx.doi.org/10.1148/radiology.138.2.7455128] [PMID: 7455128]
[9]
Memon, S.A.; Laghari, N.A.; Qureshi, S.T.; Mehdi, F. Assessment of molybdenum breakthrough levels in molybdenum-99/technetium-99m generators: One year experience at NIMRA Jamshoro Pakistan. Int. J. Radiation Res., 2014, 12(4), 343-346.
[10]
W.M, Haynes., CRC Handbook of Chemistry and Physics. 2014.
[11]
Emilio, S.C.S. Wu; Some fission products of uranium. Phys. Rev., 1940, 57, 552.
[http://dx.doi.org/10.1103/PhysRev.57.552.3]
[12]
Banerjee, S.; Pillai, M.R.; Ramamoorthy, N. Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med., 2001, 31(4), 260-277.
[http://dx.doi.org/10.1053/snuc.2001.26205] [PMID: 11710769]
[13]
Simon, Cherry; James, Sorenson.; Michael, Phelps Physics.in Nuclear Medicine; USA: Elsevier Health Sciences, 2012.
[14]
Des Plaines, IL IMV Medical Information Division.Nuclear medicine Census Market summary report., 2003.
[15]
Des Plaimes, IL IMV Medical Information Division, Nuclear Medicine Cesus Market Summary Report IMV IMV 2001.
[16]
Subramanian, G.; McAfee, JG.; Blair, RJ.; Kallfelz, FA.; Thomas, FD. Tc-99m methylene diphosphonate a superior agent for skeletal imaging, comparison with other technetium complexes. J. ournal of nuclar medicine., 1975, 16(8), 744-755.
[17]
Bevan, J.A.; Tofe, A.J.; Benedict, J.J.; Francis, M.D.; Barnett, B.L. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model. J. Nucl. Med., 1980, 21(10), 967-970.
[PMID: 6252299]
[18]
Vieillevigne, L.; Molinier, J.; Brun, T.; Ferrand, R. Gamma index comparison of three VMAT QA systems and evaluation of their sensitivity to delivery errors. Phys. Med., 2015, 31(7), 720-725.
[http://dx.doi.org/10.1016/j.ejmp.2015.05.016] [PMID: 26095758]
[19]
Callahan, R.J.; Chilton, H.M.; Ponto, J.A.; Swanson, D.P.; Royal, H.D.; Bruce, A.D. Procedure guideline for the use of radiopharmaceuticals 4.0. J. Nucl. Med. Technol., 2007, 35(4), 272-275.
[http://dx.doi.org/10.2967/jnmt.107.044156] [PMID: 18006598]
[20]
Arumugam, S.; Xing, A.; Young, T.; Thwaites, D.; Holloway, L. Comparison of three commercial dosimetric systems in detecting clinically significant VMAT delivery errors. Phys. Med., 2016, 32(10), 1238-1244.
[http://dx.doi.org/10.1016/j.ejmp.2016.09.016] [PMID: 27717741]
[21]
Kevin, J. Donohoe; Manuel L. Brown; Robert F. Carretta; Robert E. Henkin; Robert E. O’Mara; and Henry D; Royal Society of Nuclear Medicine Procedure Guideline for Bone Scintigraphy, 2003, pp. 205-209.
[22]
Helena, R. Balon, Chair; Edward B. Silberstein; Donald A. Meier; N. David Charkes; Henry D. Royal; Salil D. Sarkar; Kevin J.Donohoe Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement , 2006; pp. 1-4.
[23]
William, H. Strauss; D. Douglas, Miller; Mark D, Wittry; Manuel D, Cerqueira; Ernest V, Garcia; Abdulmassi S, Iskandrian; Heinrich R, Schelbert; Frans J, Wackers; Helena R, Balon; Otto, Lang; and Josef, Machac. In: Society of Nuclear Medicine Procedure Guideline for Myocardial Perfusion Imaging; , 2008; pp. 155-161.
[24]
Pereira, J.M.; Stabin, M.G.; Lima, F.R.; Guimarães, M.I.; Forrester, J.W. Image quantification for radiation dose calculations--limitations and uncertainties. Health Phys., 2010, 99(5), 688-701.
[http://dx.doi.org/10.1097/HP.0b013e3181e28cdb] [PMID: 20938240]